DOJ, Drugmakers Renew Disputes Over Charitable Foundations

Two lawsuits — one against federal health regulators by a drugmaker and the other against a drugmaker by the Dept. of Justice — represent the latest salvos in the dispute over whether and how drug company-supported charities can help patients pay for expensive medications.

The two suits may ultimately offer a chance to clarify what manufacturers can and cannot do to fund copay assistance charities, particularly for patients with rare diseases, says Lance Grady, who leads the market access practice at Avalere Health.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today